Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE 8: darolutamide with or without stereotactic body radiation therapy in oligometastatic castration-resistant prostate cancer
2023-507482-26-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of darolutamide in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Unicancer. Primary endpoint: Radiographic progression-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
darolutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2023-507482-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507482-26-00.